Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Eskens
CICILIA, NCT04260529 / 2019-003317-33: CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations	Completed	1/2	60	Europe	CyPep-1, Pembrolizumab 25 MG/ML [KEYTRUDA®], KEYTRUDA®	Cytovation AS, Merck Sharp & Dohme LLC	Advanced Solid Tumor Malignancy	07/24	07/24
Catalyst, NCT05383170 / 2021-006804-34: A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers	Completed	1/2	6	Europe, US	CyPep-1, Pembrolizumab 25 MG/ML [KEYTRUDA®], KEYTRUDA®	Cytovation AS, Merck Sharp & Dohme LLC	Advanced Head and Neck Squamous Cell Carcinoma, Advanced Breast Cancer, Advanced Melanoma	09/24	09/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Eskens
CICILIA, NCT04260529 / 2019-003317-33: CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations	Completed	1/2	60	Europe	CyPep-1, Pembrolizumab 25 MG/ML [KEYTRUDA®], KEYTRUDA®	Cytovation AS, Merck Sharp & Dohme LLC	Advanced Solid Tumor Malignancy	07/24	07/24
Catalyst, NCT05383170 / 2021-006804-34: A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers	Completed	1/2	6	Europe, US	CyPep-1, Pembrolizumab 25 MG/ML [KEYTRUDA®], KEYTRUDA®	Cytovation AS, Merck Sharp & Dohme LLC	Advanced Head and Neck Squamous Cell Carcinoma, Advanced Breast Cancer, Advanced Melanoma	09/24	09/24